Acasti Pharma

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002, and is headquartered in Princeton, NJ.

The stock price of Acasti Pharma Inc (NASDAQ: ACST – TSX-V: ACST) is trading at over 30% pre-market as of 6:02 AM ET. This is why it happened.

ACST Stock Price Increases Over 30% Pre-Market: Why It Happened

Corcept Therapeutics

Kaleido Biosciences Inc

Transmedics Group Inc

Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) (FRA:A1PA), which is currently going through a review process aimed at enhancing shareholder value, posted Tuesday its fiscal third-quarter results to end-December last year.  In the statement, the biopharma said it believes it has enough cash to fund it through this process, or at least the next 12 months.

Acasti Pharma posts fiscal third quarter results as strategic review continues

LAVAL, Quebec, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020.

Acasti Pharma Announces Results for Third Quarter of Fiscal 2021

The stock price of Acasti Pharma Inc (NASDAQ: ACST) is trading at over 12% pre-market. This is why it happened.

ACST Stock Price Increases Over 12% Pre-Market: Why It Happened

Acasti Pharma (ACST) stock is on the rise Monday with heavy trading of its shares despite a lack of news concerning the company. The post ACST Stock Alert: 13 Things for Acasti Pharma Investors to Know as Shares Rocket Monday appeared first on InvestorPlace.

ACST Stock Alert: 13 Things for Acasti Pharma Investors to Know as Shares Rocket Monday

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acasti (ACST) Moves to Buy: Rationale Behind the Upgrade

LAVAL, Québec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company's management and Board of Directors are unaware of any material change in the Company's operations that would account for the recent increase in market activity.

Acasti Pharma Unaware of Any Material Change

ACST stock is up more than 100% on Wednesday without any news about Acasti Pharma. Here's what you should know.

ACST Stock: 13 Things to Know as Acasti Pharma Shares Soar 100%

LAVAL, Quebec, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) today provided a business update and announced its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020.

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021

Additional analyses of TRILOGY data underway Additional analyses of TRILOGY data underway

Acasti Announces Review Process of Strategic Alternatives

LAVAL, Québec, Sept.  16, 2020  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the responsibilities formerly held by Jean-Francois Boily, Vice-President, Finance, who recently resigned.

Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

LAVAL, Québec, Sept.  11, 2020  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular and management proxy statement (the “Circular”) for its upcoming annual and special meeting of shareholders to be held on September 30, 2020 (the “Meeting”). The Meeting will take place at 1:00 p.m. Eastern Time, online only, via a virtual meeting portal, through which shareholders of the Company can listen to the Meeting, submit questions and vote online. For more information regarding the Meeting and how to attend and vote at the Meeting, shareholders can consult the Circular, which is available under the Company’s profiles on SEDAR at  www.sedar.com  and on EDGAR at  www.sec.gov .

Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint

Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

What Makes Acasti (ACST) a New Buy Stock

LAVAL, Québec, July  31, 2020  (GLOBE NEWSWIRE) --  Acasti Pharma Inc.  (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced it has completed its revisions to the pre-specified Statistical Analysis Plan (SAP) for the TRILOGY 2 Phase 3 trial of CaPre, and has filed it with the Food and Drug Administration (FDA).

Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.

Why Acasti Pharma's Stock Is Trading Higher Today

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment  as likely contributor to unusually high placebo effect in TRILOGY 1

Acasti Pharma Provides Fiscal 2020 Year-End Business Update

Plans to report summary of Trilogy 1 data on June 29, 2020 conference call Plans to report summary of Trilogy 1 data on June 29, 2020 conference call

Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

FDA response expected on or before June 30, 2020

Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

LAVAL, Québec, April  01, 2020  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and   commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has filed its meeting request with the Food and Drug Administration (FDA). The meeting is intended to discuss TRILOGY 1 data, and gain alignment with the FDA on the interpretation of the results.  The Company will also seek the FDA’s input on Acasti’s proposed revisions to the pre-specified TRILOGY 2 statistical analysis plan (SAP), and explore and agree on a plan for pooling the data from TRILOGY 1 and TRILOGY 2 in support of an NDA filing.  Acasti remains blinded to the TRILOGY2 results, and intends to update the statistical analysis plan (SAP) with these revisions if the FDA agrees. As previously noted, upon submission of the meeting request, Acasti anticipates meeting with the FDA in the second half of June.

Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

LAVAL, Québec, Feb.  28, 2020  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced that on February 28, 2020, it received written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) for failing to maintain a minimum bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) – bid price (the “Minimum Bid Price Rule”).

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital.

News for Acasti Pharma Stock (ACST)